Capital Impact Advisors, LLC Krystal Biotech, Inc. Transaction History

Capital Impact Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $41,367 - $68,691	-383 Reduced 6.69%	5,343 $950,000
Q1 2023 May 23, 2023	BUY	$72.39 - $84.27 $22,223 - $25,870	307 Added 5.67%	5,726 $458,000
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $16,984 - $21,493	269 Added 5.22%	5,419 $429,000
Q3 2022 Nov 21, 2022	BUY	$64.85 - $82.4 $56,549 - $71,852	872 Added 20.38%	5,150 $395,000
Q2 2022 Aug 15, 2022	BUY	$48.93 - $73.47 $209,322 - $314,304	4,278 New	4,278 $281,000

266

25M

270K

172K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.52B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.